Trial Profile
Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Aflibercept; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Panitumumab
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms SAMCO-PRODIGE 54
- 13 Sep 2022 Primary endpoint has been met. (Progression-free survival (PFS) according to the investigator), as per Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 07 Sep 2022 According to Merck & Co media release, results from this trial will be presented at European Society of Medical Oncology (ESMO) 2022 (LBA23).